Quest of biomarkers for venetoclax-treated CLL
- PMID: 31296538
- DOI: 10.1182/blood.2019001189
Quest of biomarkers for venetoclax-treated CLL
Conflict of interest statement
Conflict-of-interest disclosure: D.R. reports honoraria from Abbvie, Janssen, Roche, Gilead, AstraZeneca, and Verastem, and research grants from Abbvie, Janssen, Gilead, and Cellestia.
Comment on
-
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.Blood. 2019 Jul 11;134(2):111-122. doi: 10.1182/blood.2018882555. Epub 2019 Apr 25. Blood. 2019. PMID: 31023700 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources

